 In fact the Hopkins published preliminary results of a clinical study testing the basic immunotransplant concept in acute myeloid leukemia  demonstrating encouraging signals of enhanced anti-tumor immunity.To continue the clinical translation of this approach, in August 2009 the Stanford group initiated a phase I/II clinical trial for patients with newly diagnosed mantle cell lymphoma.That study uses a whole-cell, CpG-activated, autologous tumor vaccine to induce anti-tumor immunity followed by leukapheresis and re-infusion of the vaccine-primed cells immediately after standard autologous transplant.